Workflow
Is Moderna Stock a Buy Now That It's a 2-Product Company?
MRNAModerna(MRNA) The Motley Fool·2024-06-03 10:07

The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (MRNA -5.90%). Biotech stocks generally rise after a product they spent years developing earns marketing approval, but this isn't what happened. Why Moderna stock fell Moderna's bizarre stock price performance during the week ending May 31 had two main factors. First, enthusiasm for the vaccine dev ...